Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | M032 |
Trade Name | |
Synonyms | M 032|M-032|NSC 733972 |
Drug Descriptions |
M032 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12, which may result in increased anti-tumor immune response and decreased tumor cells proliferation (PMID: 33524948; NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C114294 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
M032 | M032 | 0 | 1 |
M032 + Pembrolizumab | M032 Pembrolizumab | 0 | 1 |